TY - JOUR
T1 - Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
AU - Yamagami, Wataru
AU - Aoki, Daisuke
N1 - Publisher Copyright:
© 2015 Japan Society of Obstetrics and Gynecology.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. Here we present the Treatment Annual Report for 2007. Data on the prognosis of 3381 patients with cervical cancer, 3681 with endometrial cancer, and 2367 with ovarian cancer for whom treatment was initiated in 2007 were analyzed in the Treatment Annual Report. In the 2007 Treatment Annual Report, stage I accounted for 53.1%, stage II for 24.4%, stage III for 14.2%, and stage IV for 8.3% of all patients with cervical cancer. Stage I accounted for 64.8%, stage II for 8.2%, stage III for 20.2%, and stage IV for 6.9% of all patients with endometrial cancer. Stage I accounted for 41.4%, stage II for 9.9%, stage III for 30.6%, and stage IV for 8.6% of all patients with ovarian cancer. The 5-year overall survival rates for patients with cervical cancer were 91.8% for stage I, 71.5% for stage II, 53.0% for stage III, and 23.7% for stage IV; those for patients with endometrial cancer were 95.3%, 89.8%, 75.6%, and 29.1%, and those for patients with ovarian surface epithelial-stromal tumors were 91.5%, 76.1%, 46.9%, and 31.3%, respectively.
AB - The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. Here we present the Treatment Annual Report for 2007. Data on the prognosis of 3381 patients with cervical cancer, 3681 with endometrial cancer, and 2367 with ovarian cancer for whom treatment was initiated in 2007 were analyzed in the Treatment Annual Report. In the 2007 Treatment Annual Report, stage I accounted for 53.1%, stage II for 24.4%, stage III for 14.2%, and stage IV for 8.3% of all patients with cervical cancer. Stage I accounted for 64.8%, stage II for 8.2%, stage III for 20.2%, and stage IV for 6.9% of all patients with endometrial cancer. Stage I accounted for 41.4%, stage II for 9.9%, stage III for 30.6%, and stage IV for 8.6% of all patients with ovarian cancer. The 5-year overall survival rates for patients with cervical cancer were 91.8% for stage I, 71.5% for stage II, 53.0% for stage III, and 23.7% for stage IV; those for patients with endometrial cancer were 95.3%, 89.8%, 75.6%, and 29.1%, and those for patients with ovarian surface epithelial-stromal tumors were 91.5%, 76.1%, 46.9%, and 31.3%, respectively.
KW - Japan
KW - annual report
KW - cervical cancer
KW - endometrial cancer
KW - gynecologic cancers
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=84946559263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946559263&partnerID=8YFLogxK
U2 - 10.1111/jog.12833
DO - 10.1111/jog.12833
M3 - Article
C2 - 26420746
AN - SCOPUS:84946559263
SN - 1341-8076
VL - 41
SP - 1861
EP - 1869
JO - Journal of Obstetrics and Gynaecology Research
JF - Journal of Obstetrics and Gynaecology Research
IS - 12
ER -